Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Natera Inc.

BTIG analyst Mark Massaro maintained a Buy rating on Natera yesterday and set a price target of $290.00. The company’s shares closed yesterday at $...

Natera (NTRA) Gets a Buy from BTIG

Bernstein analyst Eve Burstein maintained a Buy rating on Natera yesterday and set a price target of $310.00. The company’s shares closed yesterday...

Bernstein Sticks to Their Buy Rating for Natera (NTRA)

WSW, NY, July 16th, 2026, FinanceWire On June 19, Seegnal Inc. (TSXV:SEGN) said it had begun running its first pilot in the United States, the comp...

Canadian AI Microcap Cut Hospital Drug Alerts by 94%. Now It’s Entering the U.S. (TSXV: SEGN)

Goldman Sachs analyst Evie Koslosky maintained a Hold rating on Natera yesterday and set a price target of $270.00. The company’s shares closed tod...

Goldman Sachs Reaffirms Their Hold Rating on Natera (NTRA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Natera (NTRA) and Ionis Pharmaceuticals (IONS) with ...

Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Ionis Pharmaceuticals (IONS)

Natera ( ($NTRA) ) has shared an update. On July 1, 2026, Natera director Monica Bertagnolli informed the company’s Board that she would resign fro...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NTRA	$258.03	-1.51%	977.59K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NTRA	$258.03	-1.5%	977.59K
3
4
5
6

NTRA

NTRA

Get Natera Inc. Data in Excel

Get Natera Inc. Data in Excel